SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection?
- Theodoros Androutsakos
- , Narjes Nasiri-Ansari
- , Athanasios-Dimitrios Bakasis
- , Ioannis Kyrou
- , Efstathios Efstathopoulos
- , Harpal S. Randeva*
- , Eva Kassi*
*Corresponding author for this work
- Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Unit of Molecular Endocrinology, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens,11527 Athens, Greece
- 2nd Department of Radiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, CV2 2DX, United Kingdom; Warwick Medical School, University of Warwick, Coventry, CV4 7AL, United Kingdom
- Unit of Molecular Endocrinology, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens,11527 Athens, Greece; Endocrine Oncology Unit, 1st Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
Research output: Contribution to journal › Review article › peer-review
137
Link opens in a new tab
Citations
(SciVal)
19
Downloads
(Pure)